Status:
TERMINATED
Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)
Lead Sponsor:
University of Kansas Medical Center
Conditions:
Benign Prostatic Hyperplasia
Eligibility:
All Genders
18+ years
Brief Summary
To determine if the prior prolonged use of medication, as a treatment for benign prostatic hyperplasia, reduces the efficacy of Holmium laser enucleation of the prostate (HoLEP) for patients with beni...
Detailed Description
Experience from clinic has suggested that men who receive medication for long periods of time, defined as over a year for study purposes, have a poorer response to surgical treatment for benign prosta...
Eligibility Criteria
Inclusion
- Patients must be 18 years of age or older
- Patients must present to clinic with a diagnosis of benign prostatic hyperplasia with lower urinary tract symptoms
- Patients must be scheduled to undergo a holmium laser prostate surgery (enucleation or ablation)
Exclusion
- Patients who are under 18 years of age are not eligible.
- Patients who have a diagnosis of bladder cancer are not eligible.
- Patient who have a diagnosis of prostate cancer are not eligible.
- Patients with an elevated prostate-specific antigen (PSA) suggesting prostate cancer are not eligible unless patient has prior negative prostate biopsy.
- Patients who have acute prostatitis, a prostate abscess, or neurogenic bladder are not eligible
Key Trial Info
Start Date :
November 15 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 27 2024
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT03768765
Start Date
November 15 2018
End Date
August 27 2024
Last Update
October 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Health System
Kansas City, Kansas, United States, 66160